Evidence map›Paper›PMID 40354181›Full record

ReviewClinical pharmacology and therapeutics2025

HIV Pharmacology Data Repository: Setting the New Information-Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies.

Lauren A R Tompkins, Adrian Khoei, Oleg Kapeljushnik, Julie Dumond, Angela D M Kashuba, Alexander Tropsha, Robert Hubal, Mackenzie L Cottrell

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lauren A R TompkinsDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0009-0002-8503-9686
Adrian KhoeiDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8399-5263
Oleg KapeljushnikRenaissance Computing Institute at UNC (RENCI), Chapel Hill, North Carolina, USA.
Julie DumondDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-3500-5819
Angela D M KashubaDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alexander TropshaDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Robert HubalRenaissance Computing Institute at UNC (RENCI), Chapel Hill, North Carolina, USA.
Mackenzie L CottrellDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-0291-5111

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
HIV Pharmacology Data RepositoryU24AI181685 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mackenzie Cottrell, Julie Brumer Dumond · 2024 to 2026
$1.5M
NIAID NIH HHS P30 AI050410NIAID NIH HHS U24 AI181685
6 · The paper itself

Abstract

Drug development approaches increasingly harness computational modeling to predict drug behavior. These in silico approaches, collectively termed "pharmacometrics", have significant value in deriving biological meaning from the analysis of pooled drug concentration vs. time (CvT) datasets. However, the field lacks standardization for pharmacokinetic data description, requiring expert annotation to enable aggregate mining and sharing. These limitations impede data sharing and preservation as mandated by current NIH policies. To this end, we propose a minimum information standard for pharmacokinetic studies composed of three categories (Intervention, System, and Concentration). We implement this standard in the development of a web-based database: the HIV Pharmacology Data Repository (HIV PDR). We describe our technical approach for creating the HIV PDR, the protocols we established for standardized data deposition, and the current content of the database. We also demonstrate the utility of the HIV PDR for pharmacometrics research through computational modeling of CvT data extracted from this new database. Based on these efforts, we propose the HIV PDR as a standard to preserve and share pharmacokinetic data generated through preclinical and clinical HIV research.

Indexed as

Anti-HIV AgentsDatabases, FactualHIV InfectionsInformation DisseminationComputer SimulationDrug DevelopmentDrug Evaluation, PreclinicalHumansAnti-HIV Agents

Identifiers

PMID40354181
PMCPMC12922803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.